<u>REMARKS</u>

In the present Amendment, claim 13 has been amended to incorporate the subject matter of allowed claim 11.

Claims 1-10, 12 and 14-23 were previously canceled.

No new matter has been added and entry of the Amendment is respectfully requested.

Upon entry of the Amendment, claims 11, 13 and 24-41 will be all the claims pending in the application.

Applicants note with appreciation that claims 11 and 24-38 are allowed.

I. Response to Rejection Under 35 U.S.C. § 102/103

Claims 13 and 39-41 are rejected under 35 U.S.C. §102(b) as allegedly anticipated by or, in the alternative, under 35 U.S.C. § 103(a) as allegedly obvious over Masutomi et al, Yamashita et al or Budz et al.

Applicants respectfully submit that the present claims are novel and patentable over the cited references. As described above, Applicants have amended claim 13 to incorporate the preparation of the gold sulfide colloid as recited in allowed claim 11. Accordingly, the Examiner is respectfully requested to reconsider and withdraw the rejection.

II. <u>Conclusion</u>

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the

Attorney Docket Q81115

AMENDMENT UNDER 37 C.F.R. § 1.116

U.S. Application No.: 10/825,672

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 51,283

Fang Liu

SUGHRUE MION, PLLC

Telephone: (202) 293-7060 Facsimile: (202) 293-7860

> WASHINGTON OFFICE 23373 CUSTOMER NUMBER

Date: October 14, 2005